This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
This hospital-based cohort study will be conducted on 80 adult hepatitis B surface antigen (HBsAg) carriers presented to the Tropical Medicine and Gastroenterology outpatient clinic, at Sohag University Hospital Exclusion criteria Patients with serological evidence of HCV. HBV patients who had received or are currently under anti-viral therapy. Alcohol consumption. Decompensated liver disease. Patients with HCC. Patients are known to have another chronic liver disease (e.g. autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, Haemochromatosis, or drug-induced chronic hepatitis). Patients with contraindications to liver biopsy such as uncooperative patients, prothrombin time (PT) \>4 seconds more than control, INR greater than 1.6, platelets count \<100.000/mm3After taking informed written consent, the participants will be subjected to: Clinical evaluation: medical history and physical examination. Laboratory investigations: Complete blood count. Prothrombin time and concentration. Liver function tests Anti-HCV. HBeAg. HBV DNA. Abdominal ultrasonography Ultrasound-guided percutaneous liver biopsy
Study Type
OBSERVATIONAL
Enrollment
91
liver biopsy were taken then evaluated by histopathological examination
Faculty of medicine
Sohag, Egypt
prevalence of hepatic steatosis in CHB
Number of cases with hepatic steotosis in CHB
Time frame: January 2023 to july 2023 will be included in the study
degree of hepatic steatosis in CHB
Mild, or Moderate or severe degree
Time frame: January 2023 to july 2023 will be included in the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.